X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1948) 1948
cytosine-arabinoside (1621) 1621
oncology (1208) 1208
hematology (1076) 1076
female (987) 987
male (979) 979
middle aged (784) 784
adult (775) 775
cytosine arabinoside (712) 712
acute myelogenous leukemia (670) 670
cytarabine - administration & dosage (647) 647
chemotherapy (586) 586
aged (573) 573
antineoplastic combined chemotherapy protocols - therapeutic use (549) 549
index medicus (531) 531
acute myeloid-leukemia (515) 515
animals (460) 460
dose cytosine-arabinoside (456) 456
adolescent (447) 447
cytarabine (447) 447
leukemia, myeloid, acute - drug therapy (430) 430
treatment outcome (366) 366
therapy (364) 364
remission induction (357) 357
leukemia (353) 353
acute nonlymphocytic leukemia (352) 352
acute myeloid leukemia (327) 327
cancer (327) 327
cytarabine - pharmacology (319) 319
acute disease (315) 315
ara-c (313) 313
colony-stimulating factor (301) 301
pharmacology & pharmacy (286) 286
cytarabine - adverse effects (270) 270
child (269) 269
cytarabine - therapeutic use (261) 261
prognosis (251) 251
leukemia, myeloid - drug therapy (240) 240
antineoplastic combined chemotherapy protocols - adverse effects (232) 232
dose-response relationship, drug (228) 228
mice (227) 227
acute lymphoblastic-leukemia (209) 209
daunorubicin (206) 206
survival rate (193) 193
child, preschool (192) 192
bone-marrow transplantation (191) 191
disease-free survival (191) 191
survival analysis (171) 171
antineoplastic combined chemotherapy protocols - administration & dosage (170) 170
cells (169) 169
aged, 80 and over (168) 168
recurrence (166) 166
antineoplastic agents - therapeutic use (163) 163
acute myeloblastic-leukemia (160) 160
aml (153) 153
apoptosis (152) 152
drug administration schedule (152) 152
mitoxantrone (151) 151
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (145) 145
leukemia, myeloid, acute - mortality (138) 138
toxicity (138) 138
infant (137) 137
myelodysplastic syndromes (137) 137
tumor cells, cultured (136) 136
biochemistry & molecular biology (135) 135
time factors (135) 135
1-beta-d-arabinofuranosylcytosine (132) 132
leukemia, myeloid, acute - pathology (130) 130
transplantation (129) 129
etoposide - administration & dosage (128) 128
rats (127) 127
retrospective studies (126) 126
bone marrow transplantation (123) 123
acute myelocytic-leukemia (122) 122
antineoplastic agents - pharmacology (122) 122
mitoxantrone - administration & dosage (121) 121
cells, cultured (120) 120
pediatrics (118) 118
risk factors (118) 118
antimetabolites, antineoplastic - therapeutic use (117) 117
combined modality therapy (117) 117
medicine & public health (116) 116
in-vitro (114) 114
cytidine deaminase (113) 113
induction (112) 112
neurosciences (112) 112
antimetabolites, antineoplastic - administration & dosage (111) 111
daunorubicin - administration & dosage (111) 111
antimetabolites, antineoplastic - pharmacology (110) 110
children (109) 109
bone-marrow-transplantation (108) 108
care and treatment (108) 108
high-dose cytarabine (108) 108
survival (108) 108
drug resistance, neoplasm (107) 107
pharmacokinetics (106) 106
deoxycytidine kinase (105) 105
expression (104) 104
acute promyelocytic leukemia (103) 103
idarubicin (103) 103
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2849) 2849
French (25) 25
German (25) 25
Russian (15) 15
Spanish (11) 11
Japanese (7) 7
Czech (3) 3
Polish (3) 3
Korean (2) 2
Chinese (1) 1
Hungarian (1) 1
Italian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 25, pp. 5006 - 5014
Journal Article
Experimental Hematology, ISSN 0301-472X, 06/2019, Volume 74, pp. 13 - 18.e3
Cytarabine remains the backbone of therapy in acute myeloid leukemia (AML). The ability to assess intracellular cytarabine triphosphate (ara-CTP) levels in... 
AML | MEDICINE, RESEARCH & EXPERIMENTAL | CYTOSINE-ARABINOSIDE | CLEARANCE | METABOLISM | PERIPHERAL-BLOOD | 1-BETA-D-ARABINOFURANOSYLCYTOSINE | BIOSENSOR | HEMATOLOGY | CELL | EXPRESSION
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 09/2015, Volume 100, Issue 9, pp. 1172 - 1179
Serial studies have demonstrated that induction therapy with FLAM [flavopiridol 50 mg/m(2) days 1-3, cytarabine 667 mg/m(2)/day continuous infusion days 6-8,... 
ADULT PATIENTS | CYTOSINE-ARABINOSIDE | BONE-MARROW BIOPSY | INDUCTION THERAPY | EUROPEAN LEUKEMIANET | TIMED SEQUENTIAL THERAPY | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOCYTIC-LEUKEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY | TUMOR LYSIS SYNDROME
Journal Article
AMERICAN NATURALIST, ISSN 0003-0147, 09/2019, Volume 194, Issue 3, pp. 432 - 438
We previously demonstrated that treatment with the demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) alters the offspring sex ratios produced by females of... 
5-aza-2 '-deoxycytidine | CYTOSINE-ARABINOSIDE | DECITABINE | HYMENOPTERA | METHYLTRANSFERASE | 5-AZACYTIDINE | DNA METHYLATION CHANGES | CYTIDINE DEAMINASE | EVOLUTIONARY BIOLOGY | INHIBITION | Nasonia vitripennis | DNA methylation | 5-AZA-2-DEOXYCYTIDINE | ECOLOGY | DIFFERENTIATION | sex ratio
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2011, Volume 29, Issue 19, pp. 2696 - 2702
Purpose To assess the optimal cumulative dose of cytarabine for treatment of young adults with acute myeloid leukemia (AML) within a prospective multicenter... 
ADULT PATIENTS | POSTREMISSION THERAPY | MANAGEMENT | ONCOLOGY | RECOMMENDATIONS | BONE-MARROW-TRANSPLANTATION | CYTOSINE-ARABINOSIDE THERAPY | MUTATIONS | STEM-CELL TRANSPLANTATION | CHEMOTHERAPY | REMISSION
Journal Article
Blood, ISSN 0006-4971, 03/2008, Volume 111, Issue 5, pp. 2556 - 2562
Multisystem Langerhans cell histiocytosis (MS-LCH) is associated with high mortality when patients have risk organ involvement (RO+) or are younger than 2... 
CYTOSINE-ARABINOSIDE | ETOPOSIDE | RISK | DYSFUNCTION | LEUKEMIA | HEMATOLOGY | SOCIETY | CHEMOTHERAPY | RANDOMIZED TRIAL | CHILDREN | TRANSPLANTATION | Histiocytosis, Langerhans-Cell - therapy | Demography | Humans | Risk Factors | Child, Preschool | Female | Infant | Male | Survival Rate | Treatment Outcome
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1249 - 1259
Patients with AML who were between 17 and 60 years of age were randomly assigned to receive induction therapy with the standard dose of daunorubicin or twice... 
CYTOSINE-ARABINOSIDE | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | INDUCTION CHEMOTHERAPY | ACUTE NONLYMPHOCYTIC LEUKEMIA | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOCYTIC-LEUKEMIA | GROUP-B | DAUNORUBICIN | REMISSION INDUCTION | UNTREATED ADULT PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Acute - drug therapy | Stem Cell Transplantation | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myelomonocytic, Acute - therapy | Adult | Female | Remission Induction - methods | Daunorubicin - administration & dosage | Leukemia, Myelomonocytic, Acute - genetics | Histone-Lysine N-Methyltransferase | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Combined Modality Therapy | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Myeloid-Lymphoid Leukemia Protein - genetics | Adolescent | Infusions, Intravenous | Mutation | Leukemia, Myelomonocytic, Acute - mortality | Anthracyclines | Usage | Daunorubicin | Young adults | Health aspects | Bone marrow | Chemotherapy | Consolidation | Kinases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 11, pp. 1027 - 1036
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1025 - 1036
Journal Article